Nov 14, 2025 12:14AM Palatin Technologies (PTN) reported Q1 result

Oct 2, 2025 05:00PM PharmaCorp closes three pharmacy acquisitions across Canada

May 9, 2025 07:30AM Internet Patents (PTNT) vPresents Promising Preclinical Data on Melanocortin Agonists for Retinopathy

May 7, 2025 05:26PM Palatin Technologies (PTN) to be delisted from NYSE American

May 7, 2025 12:33PM Palatin Technologies (PTN) Halted, News Pending

May 7, 2025 08:15AM Palatin Technologies (PTN) Expects $11.5M Financing to Cure NYSE American Delisting Notice

May 7, 2025 08:01AM Palatin Technologies (PTN) Prices 76.67M Share Offering at $0.15/sh

Apr 29, 2025 07:30AM Palatin Technologies (PTN) Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease

Apr 17, 2025 07:30AM Palatin Technologies (PTN) Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Apr 14, 2025 07:01AM Palatin Technologies (PTN) Appeals NYSE American Notice of Delisting

Apr 10, 2025 04:01PM Palatin Technologies (PTN) Receives NYSE Delisting Decision, Plans to Appeal

Apr 10, 2025 07:30AM Palatin Technologies (PTN) to Present Positive Phase 2b Data for Melanocortin Agonist

Mar 31, 2025 07:36AM Palatin Technologies (PTN) Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

Mar 28, 2025 07:30AM Palatin Technologies (PTN) Announces Positive Topline Results from Phase 2 Ulcerative Colitis Study of PL8177

Mar 25, 2025 07:31AM Palatin Technologies' (PTN) PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

Feb 13, 2025 07:35AM Palatin Technologies (PTN) Tops Q2 EPS by 39c

Feb 7, 2025 08:00AM Palatin Technologies (PTN) Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement

Feb 6, 2025 07:32AM Palatin Technologies (PTN) Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide

Jan 28, 2025 07:31AM Palatin Technologies (PTN) Provides Update on Anticipated 2025 Corporate Milestones

Dec 19, 2024 07:31AM Palatin Technologies (PTN) Announces Positive Phase IIb BREAKOUT Study Results

Dec 16, 2024 07:31AM Palatin Technologies (PTN) Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds

Nov 26, 2024 07:06AM H.C. Wainwright Reiterates Buy Rating on Palatin Technologies (PTN)

Nov 14, 2024 07:34AM Palatin Technologies (PTN) Misses Q1 EPS by 18c

Oct 22, 2024 04:33PM Palatin Technologies (PTN) Files for 4.85M Share Offering by Selling Stockholders

Oct 7, 2024 04:15PM Palatin Technologies (PTN) Receives NYSE Non-compliance Notice

Oct 1, 2024 02:16PM H.C. Wainwright Reiterates Buy Rating on Palatin Technologies (PTN)

Oct 1, 2024 07:32AM Palatin Technologies (PTN) Actively Engaged With Multiple Parties for Potential Funding Sources for Future Operating Cash Needs

Oct 1, 2024 07:32AM Palatin Technologies (PTN) Misses Q4 EPS by 3c

Sep 9, 2024 07:31AM Palatin Technologies (PTN) Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

Aug 28, 2024 07:30AM Palatin Technologies (PTN) Reports FDA Confirmed Acceptability of Remaining Phase 3 Trials for PL9643

Aug 22, 2024 07:30AM Palatin Technologies (PTN): First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity

Jul 25, 2024 04:49PM Palatin Technologies (PTN) Files for 4.85M Share Offering by Selling Stockholders

Jun 21, 2024 08:00AM Palatin Technologies (PTN) Receives $6.1M from Exercise of Warrants

Jun 21, 2024 06:35AM H.C. Wainwright Reiterates Buy Rating on Palatin Technologies (PTN)